Jesster I'd agree with you that the primary trial here was aimed at one cancer, GBM. In the past I've seen companies do single cancer trials for pancreatic cancer. Those companies all expressed the belief that if they could gain approval in pancreatic, they'd be approved for many other solid cancers. They failed in pancreatic and the companies failed.
I think GBM is as tough as pancreatic, and in one way tougher, the blood-brain barrier. If the other companies were right about pancreatic, I don't know that we may not be right about approval in GBM.
I should add that there is some anecdotal evidence to show that DCVax-L has benefits in other cancers, including pancreatic, but I have no idea if documentation of that has been a part of the filing. The company had said they were after GBM, but if you looked at their exhibit stand at ASCO in 2023, the last time they were there, it shouted TUMOR AGNOSTIC.
To the best of my knowledge no formal presentation has been made to support this position. I do wonder if before the trials ever began the regulators agreed that a product that fights GBM might very well be effective against any solid cancer. If it's true of pancreatic, could it also be true of GBM.
From July 1st to August 11th (a span of 41 days), the total shares outstanding increased from 1,457,994,198 to 1,481,631,723. This represents a total dilution of 23,637,525 shares. (1,481,631,723 - 1,457,994,198) = 23,637,525 millions.
Market Data 
Markets 
AI
